Z160 Press Release. Good news. Should be an interesting day
CAMBRIDGE, Mass., Apr 02, 2013 (BUSINESS WIRE) -- Zalicus Inc. (nasdaq global market:ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled "Solid Dispersion Formulations and Methods of Use Thereof," provides broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain.